Press Release October 31, 2017

Kymera Therapeutics Completes $30 Million Series A Financing Round

The Life Sciences team advised Kymera Therapeutics LLC on its $30 million Series A financing round to advance a transformational new therapeutic modality and discover breakthrough medicines for patients with previously untreatable diseases. The round was led by Atlas Venture, which co-founded, seeded and incubated the company, along with Lilly Ventures and Amgen Ventures.

Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases.

The Goodwin team was led by partner William Collins and included partners Mitchell Bloom and Daniel Karelitz; and associates Katherine Maxwell and Gabriela Morales-Rivera.

For additional details on the financing, please read the press release.